Who are BAY60-4552 plus Vardenafil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bay60-4552-plus-vardenafil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BAY60-4552 plus Vardenafil — Competitive Intelligence Brief

BAY60-4552 plus Vardenafil (BAY60-4552 plus Vardenafil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble guanylate cyclase activator + phosphodiesterase-5 inhibitor combination. Area: Cardiovascular.

phase 2 Soluble guanylate cyclase activator + phosphodiesterase-5 inhibitor combination Soluble guanylate cyclase (sGC) and phosphodiesterase-5 (PDE-5) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

BAY60-4552 plus Vardenafil (BAY60-4552 plus Vardenafil) — Bayer. BAY60-4552 activates soluble guanylate cyclase to increase cGMP levels, while vardenafil inhibits phosphodiesterase-5 to prevent cGMP degradation, synergistically enhancing vasodilation and improving erectile function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BAY60-4552 plus Vardenafil TARGET	BAY60-4552 plus Vardenafil	Bayer	phase 2	Soluble guanylate cyclase activator + phosphodiesterase-5 inhibitor combination	Soluble guanylate cyclase (sGC) and phosphodiesterase-5 (PDE-5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble guanylate cyclase activator + phosphodiesterase-5 inhibitor combination class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAY60-4552 plus Vardenafil — Competitive Intelligence Brief. https://druglandscape.com/ci/bay60-4552-plus-vardenafil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab